Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | PAM | P19021 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5666555 | 0.94 | TSHR (0.67) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL5668563 | 0.92 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL10411 | 0.92 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126641 | 0.92 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126648 | 0.92 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126638 | 0.92 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL20570495 | 0.92 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126642 | 0.92 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL1843295 | 0.86 | — | — | |
| SCHEMBL11507812 | 0.86 | TSHR (0.50) | TSHRDGKAPAMMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112047998-B | Preparation method of perindopril | 上海阿达玛斯试剂有限公司 | 2024-01-09 | — | — | CN | claimed |
| US-20230148641-A1 | FLAVOR COMPOSITION | FIRMENICH SA (CH) | 2023-05-18 | — | — | US | claimed |
| EP-4125427-A1 | FLAVOR COMPOSITION | Firmenich SA (CH) | 2023-02-08 | — | — | EP | claimed |
| WO-2021198199-A1 | FLAVOR COMPOSITION | FIRMENICH SA (CH) | 2021-10-07 | — | — | WO | claimed |
| CN-107098949-B | Novel green synthesis process for preparing perindopril tert-butylamine salt | 上药东英（江苏）药业有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-112047998-A | Preparation method of perindopril | 上海阿达玛斯试剂有限公司 | 2020-12-08 | — | — | CN | claimed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | claimed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | claimed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | claimed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | claimed |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-05-26 | — | — | US | disclosed |
| US-12521386-B2 | Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-13 | — | — | US | disclosed |
| US-12509468-B2 | Quindoline compounds and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250189527-A1 | COMPOSITIONS AND METHODS FOR DETECTING, PREDICTING RISK OF DEVELOPING, AND TREATING LEPTOMENINGEAL DISEASE | DUKE UNIVERSITY | 2025-06-12 | — | — | US | disclosed |
| CN-108530502-B | Preparation method of crystalline form valrubicin | 道中道（菏泽）制药有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-0906108-A1 | METHOD OF TREATING HEART FAILURE WITH ENDOTHELIN ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-04-07 | — | — | EP | disclosed |
| US-5834483-A | Method of treating heart failure with endothelin antagonists | MERCK & CO., INC. (US) | 1998-11-10 | — | — | US | disclosed |
| US-5714479-A | TREATMENT OF HYPERTENSION, ACUTE RENAL FAILURE, ANGINA PECTORIS, ARTERIOSCLEROSIS, ASTHMA, GASTRIC ULCER AND SIMILAR AILMENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-03 | — | — | US | disclosed |
| WO-1997037665-A1 | METHOD OF TREATING HEART FAILURE WITH ENDOTHELIN ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-10-16 | — | — | WO | disclosed |
| EP-0714897-A1 | FUSED HETEROAROMATIC CYCLOPENTENE DERIVATIVE HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509468-B2 | Quindoline compounds and uses thereof | TPD52L2, BRDT, RECQL | TSHR 2558/4885DGKA 3995/4885PAM 1441/4885 |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | PTK2, ILK, FPR2 | TSHR 4402/4885DGKA 2108/4885PAM 3238/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | TSHR 3766/4885DGKA 570/4885PAM 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.